首页> 美国卫生研究院文献>Experimental and Therapeutic Medicine >Catechol-O-methyltransferase promoter hypomethylation is associated with the risk of coronary heart disease
【2h】

Catechol-O-methyltransferase promoter hypomethylation is associated with the risk of coronary heart disease

机译:儿茶酚-O-甲基转移酶启动子低甲基化与冠心病的风险有关

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Catechol-O-methyltransferase (COMT) gene variation is known to be associated with the risk of acute coronary events. The purpose of the present study was to investigate the contribution of COMT promoter methylation towards the risk of coronary heart disease (CHD). COMT methylation was evaluated in 48 CHD cases and 48 well-matched non-CHD controls using bisulfite pyrosequencing technology. The results demonstrated that CHD cases had a significantly lower level of methylation at COMT CpG3 sites compared with the controls (33.77±5.71 vs. 36.42±5.00%; P=0.018). Further analysis, according to gender, showed that CpG3 methylation was associated with CHD in males (P=0.038) but not in females (P=0.253), suggesting that there is a gender disparity in the association between COMT methylation and CHD. In conclusion, it was determined that COMT CpG3 hypomethylation is associated with an increased risk of CHD in males.
机译:已知邻苯二酚-O-甲基转移酶(COMT)基因变异与急性冠脉事件风险相关。本研究的目的是研究COMT启动子甲基化对冠心病(CHD)风险的贡献。使用亚硫酸氢盐焦磷酸测序技术对48例CHD病例和48例匹配良好的非CHD对照进行了COMT甲基化评估。结果表明,与对照组相比,CHD病例在COMT CpG3位点的甲基化水平明显降低(33.77±5.71 vs. 36.42±5.00%; P = 0.018)。根据性别进行的进一步分析显示,男性中CpG3甲基化与冠心病相关(P = 0.038),而女性则不相关(P = 0.253),这表明COMT甲基化与冠心病之间的性别差异。总之,已确定COMT CpG3甲基化过低与男性冠心病风险增加有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号